SCHEMBL4894481

SCHEMBL4894481

O=C(S)c1ccc2cnccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
MGAM O43451 1/20 0.39
CNR2 P34972 2/20 0.39
CNR1 P21554 1/20 0.39
ROCK2 O75116 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HDAC8 Q9BY41 1/20 0.36
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
DPP4 P27487 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
ERN1 O75460 1/20 0.34
NFKB1 P19838 2/20 0.33
RAB9A P51151 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27776426 0.85 KDM4E (0.50) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL1016413 0.83 MGAM (0.58) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL10201993 0.81 CTSA (0.45) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL3282791 0.81 ADORA3 (0.46) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL4729283 0.77 ALDH1A1 (0.63) CTSAHDAC3HDAC1HDAC2KDM4E
SCHEMBL327145 0.77 ALDH1A1 (0.46) CTSAHDAC3HDAC1HDAC2ROCK2
SCHEMBL12664041 0.77 CTSA (0.43) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL28187527 0.77 CTSA (0.40) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL4894482 0.76 CTSA (0.40) CTSAHDAC3HDAC1HDAC2MGAM
SCHEMBL4596658 0.75 MGAM (0.68) MGAMCNR2KDM4EHDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
US-20080207677-A1 Napthyridine Compounds As Rock Inhibitors GPC BIOTECH AG (DE) 2008-08-28 US disclosed
EP-1833832-A1 NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS GPC Biotech AG (DE) 2007-09-19 EP disclosed
WO-2007060028-A1 NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS GPC BIOTECH AG (DE) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207677-A1 Napthyridine Compounds As Rock Inhibitors ROCK2, ROCK1, RHOT2 CTSA 3764/4885HDAC3 2073/4885HDAC1 1662/4885
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP CTSA 2384/4885HDAC3 4744/4885HDAC1 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.